IL5 and asthma: Additionally, in asthma, treatment eligibility criteria for IL-5 targeting monoclonal antibodies or dupilumab includes the presence of elevated Th2 biomarkers that are predictive of a more likely patient response, such as blood eosinophils ≥ 0.30 K/μL or FeNO ≥ 25 ppb50.